Gilead Sciences to acquire ADC developer Immunomedics for $21bn

This article was originally published here

As per the terms of the deal, Gilead Sciences has offered to acquired 100% of Immunomedics for $88 per share in cash. Through the acquisition, Gilead Sciences gets

The post Gilead Sciences to acquire ADC developer Immunomedics for $21bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply